Abstract:Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the Ptpn11 gene. SHP2 regulates cell growth, differentiation and apoptosis via modulating various signaling pathways, such as RAS/ERK signaling pathway, and participates in the PD-1/PD-L1 pathway governing immune surveillance, thus has been recognized as a breakthrough antitumor therapeutic target. By stabilizing the inactive closed conformation of SHP2, allosteric inhibitors have overcome the druggability issues and advanced to clinical trials. However, the gain-of-function mutation (GOF) of the Ptpn11 gene renders SHP2 in a pathological active conformation, causing a range of developmental disorders and tumors. Overactivated SHP2 mutants undergo structural and functional changes, conferring resistance to SHP2 wild-type allosteric inhibitors. Therefore, developing novel therapeutic modality that effectively inhibits pathogenic SHP2 mutants has become an urgent need for the treatment of SHP2 related diseases. Herein, we report the design, synthesis and biological evaluation of novel SHP2 small molecule degraders based on PROTACs (proteolysis-targeting chimeras) technology by employing an allosteric inhibitor 2 targeting SHP2-activated mutant as the warhead. These SHP2(E76A) PROTACs have shown strong inhibitory activities in both enzyme and cell proliferation. Notably, the lead compounds 3f and 4d exhibit potent antiproliferative activities against both the wild-type SHP2 dependent human esophageal squamous carcinoma cell line KYSE-520 and the mutant SHP2(N58S) human large-cell lung carcinoma cell line NCI-H661, with an improvement by 5 to 10-fold compared to the positive control 2. This study provides a new therapeutic intervention strategy for treating developmental disorders and tumors caused by SHP2 mutation or activation.

Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)

Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

The Allosteric Site on SHP2’s Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment

Exploring the Existing Drug Space for Novel Ptyr Mimetic and SHP2 Inhibitors.

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis

Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening

Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2).

Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 WT and SHP2F285S by molecular dynamics study

Cross the Undruggable Barrier, the Development of SHP2 Inhibitors: from Catalytic Site Inhibitors to Allosteric Inhibitors

Small Molecule Degraders Targeting the SHP2E76A Mutant Effectively Inhibiting the Proliferation of Wild-type and Mutant SHP2 Dependent Tumor Cells

Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation